WHAT IS CLAIMED IS:

1. 1. A multispecific antibody that binds to PDL1 and CD47, comprising:

i) a first antigen-binding moiety comprising a single domain anti-PDL1 antibody that comprises a heavy chain variable region comprising:

a) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 1, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 2, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 3;

b) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 6, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 7, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 8;

c) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 11, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 13;

d) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 16, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 17, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 18;

e) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 21, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 22, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 23;

f) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 26, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 27, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 28;

g) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 31, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 32, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 33;

h) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 36, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 37, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 38;

i) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 41, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 42, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 43;

j) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 46, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 47, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48;

k) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 51, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 52, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 53;

l) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 56, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 57, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 58;

m) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 61, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 62, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 63; or

n) a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 66, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 67, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68; and

ii) a second antigen-binding moiety comprising an anti-CD47 antibody that comprises a heavy chain variable region (VH) comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 81, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 82, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 83; and a light chain variable region (VL) comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 84, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 85, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 86.

2. The multispecific antibody of claim 1, wherein the single domain antibody comprises a heavy chain variable region CDR1 comprising the amino acid sequence set forth in SEQ ID NO: 51, a heavy chain variable region CDR2 comprising the amino acid sequence set forth in SEQ ID NO: 52, and a heavy chain variable region CDR3 comprising the amino acid sequence set forth in SEQ ID NO: 53.

3. The multispecific antibody of claim 1 or 2, wherein the single domain antibody comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 9, 14, 19, 24, 29, 34, 39, 44, 49, 54, 59, 64 or 69.

4. The multispecific antibody of any one of claims 1-3, wherein the single domain antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 54.

5. The multispecific antibody of any one of claims 1-4, wherein the second antigen-binding moiety comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 87, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 88.

6. The multispecific of any one of claims 1-5, wherein the anti-CD47 antibody of the second antigen-binding moiety comprises an Fc region selected from the group consisting of the Fc regions of IgG1, IgG2, IgG3 and IgG4.

7. The multispecific of claim 6, wherein the Fc region comprises an IgG1 Fc region.

8. The multispecific antibody of any one of claims 1-7, wherein the multispecific antibody comprises a full-length immunoglobulin, a single-chain Fv (scFv) fragment, a Fab fragment, a Fab' fragment, a F(ab')2, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a VHH, a VHH-Fc fusion, an Fv-Fc fusion, a scFv-Fc fusion, a scFv-Fv fusion, a diabody, a tribody, a tetrabody or any combination thereof.

9. The multispecific antibody of any one of claims 1-8, comprising:

i) a first antigen-binding moiety comprising a single domain anti-PDL1 antibody that comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 54; and

ii) a second antigen-binding moiety comprising an anti-CD47 antibody comprising a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 87; and a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 88.

10. The multispecific antibody of any one of claims 1-9, comprising a first chain comprising the amino acid sequence set forth in SEQ ID NO: 138, and a second chain comprising the amino acid sequence set forth in SEQ ID NO: 139.

11. An immunoconjugate comprising the multispecific antibody of any one of claims 1-10, linked to a therapeutic agent.

12. The immunoconjugate of claim 11, wherein the therapeutic agent is a cytotoxin.

13. The immunoconjugate of claim 11, wherein the therapeutic agent is a radioactive isotope.

14. An antigen-recognizing receptor comprising an extracellular antigen-binding domain that comprises a multispecific antibody of any one of claims 1-10.

15. The antigen-recognizing receptor of claim 14, which is a chimeric antigen receptor (CAR) or a recombinant T cell receptor.

16. The antigen-recognizing receptor of claim 14 or 15, which is a CAR.

17. The antigen-recognizing receptor of any one of claims 14-16, wherein the multispecific antibody comprised in the extracellular antigen-binding domain comprises a VHH, a scFv, a Fab, a Fab', a di-scFv or any combination thereof.

18. The antigen-recognizing receptor of any one of claims 14-17, wherein the multispecific antibody comprised in the extracellular antigen-binding domain comprises an anti-PDL1 VHH and an anti-CD47 scFv.

19. An immunoresponsive cell comprising an antigen-recognizing receptor of any one of claims 14-18.

20. The immunoresponsive cell of claim 19, wherein the immunoresponsive cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), a regulatory T cell, a Natural Killer T (NKT) cell and a myeloid cell.

21. The immunoresponsive cell of claim 20, wherein the immunoresponsive cell is a T cell.

22. A pharmaceutical composition comprising a) the multispecific antibody of any one of claims 1-10, the immunoconjugate of any one of claims 11-13, the immunoresponsive cell of any one of claims 19-21, and b) a pharmaceutically acceptable carrier.

23. One or more nucleic acid encoding the multispecific antibody of any one of claims 1-10.

24. One or more vector comprising the nucleic acid of claim 23.

25. A host cell comprising the nucleic acid of claim 23 or the vector of claim 24.

26. A method for preparing a multispecific antibody of any one of claims 1-10 comprising expressing the multispecific antibody in the host cell of claim 25 and isolating the multispecific antibody from the host cell.

27. A pharmaceutical composition of claim 22 for use as a medicament.

28. A pharmaceutical composition of claim 22 for use in treating cancer.

29. The pharmaceutical composition of claim 28, wherein the cancer exhibits high microsatellite instability (MSI).

30. The pharmaceutical composition of claim 28, wherein the cancer is selected from the group consisting of mesothelioma, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, synovial sarcoma, thymic carcinoma, endometrial carcinoma, stomach cancer, cholangiocarcinoma, head and neck cancer, blood cancer and a combination thereof.

31. A kit comprising an antibody of any one of claims 1-10, an immunoconjugate of any one of claims 11-13, a pharmaceutical composition of claim 22, one or more nucleic acid of claim 23, one or more vector of claim 24 or an immunoresponsive cell of any one of claims 19-21.

32. The kit of claim 31, further comprising a written instruction for treating and/or preventing a neoplasm.